41.35
-0.10
(-0.24%)
At close: 1:30:14 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,136,963.00
2,150,228.00
1,940,487.00
1,780,098.00
1,754,827.00
Cost of Revenue
1,426,718.00
1,394,665.00
1,245,585.00
1,185,631.00
1,158,070.00
Gross Profit
710,245.00
755,563.00
694,902.00
594,467.00
596,757.00
Operating Expense
426,383.00
416,890.00
371,093.00
338,019.00
371,537.00
Operating Income
283,862.00
338,673.00
323,809.00
256,448.00
225,220.00
Net Non Operating Interest Income Expense
-356.00
3,461.00
-2,144.00
-70.00
-105.00
Pretax Income
136,969.00
213,678.00
410,626.00
234,760.00
223,608.00
Tax Provision
14,824.00
15,269.00
58,627.00
38,649.00
40,210.00
Net Income Common Stockholders
122,145.00
198,409.00
351,999.00
196,111.00
183,398.00
Diluted NI Available to Com Stockholders
122,145.00
198,409.00
351,999.00
196,111.00
183,398.00
Basic EPS
1.20
1.96
3.49
1.94
1.82
Diluted EPS
1.20
1.96
3.48
1.94
1.81
Basic Average Shares
101,211.97
100,989.00
100,989.00
100,989.00
100,989.00
Diluted Average Shares
101,211.97
101,150.00
101,227.00
101,234.00
101,199.00
Total Expenses
1,853,101.00
1,811,555.00
1,616,678.00
1,523,650.00
1,529,607.00
Net Income from Continuing & Discontinued Operation
122,145.00
198,409.00
351,999.00
196,111.00
183,398.00
Normalized Income
192,119.61
271,542.83
353,893.47
192,322.61
185,490.27
Interest Income
5,192.00
10,643.00
2,694.00
3,464.00
4,208.00
Interest Expense
5,548.00
7,182.00
4,838.00
3,534.00
4,313.00
Net Interest Income
-356.00
3,461.00
-2,144.00
-70.00
-105.00
EBIT
142,517.00
220,860.00
415,464.00
238,294.00
227,921.00
EBITDA
324,729.00
402,823.00
591,745.00
418,044.00
413,210.00
Reconciled Cost of Revenue
1,426,718.00
1,394,665.00
1,245,585.00
1,185,631.00
1,158,070.00
Reconciled Depreciation
182,212.00
181,963.00
176,281.00
179,750.00
185,289.00
Net Income from Continuing Operation Net Minority Interest
122,145.00
198,409.00
351,999.00
196,111.00
183,398.00
Total Unusual Items Excluding Goodwill
-78,467.00
-78,762.00
-2,210.00
4,535.00
-2,551.00
Total Unusual Items
-78,467.00
-78,762.00
-2,210.00
4,535.00
-2,551.00
Normalized EBITDA
403,196.00
481,585.00
593,955.00
413,509.00
415,761.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-8,492.39
-5,628.17
-315.53
746.61
-458.73
12/31/2020 - 1/20/2022
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
4111.TWO Chi Sheng Pharma & Biotech Co., Ltd
28.50
-0.70%
1783.TW Maxigen Biotech Inc.
49.30
-5.37%
1786.TW SciVision Biotech Inc.
111.50
-1.76%
6782.TW Visco Vision Inc.
158.50
-2.46%
4737.TW Bionime Corporation
58.50
-2.17%
6491.TW Pegavision Corporation
357.00
+0.14%
6612.TWO ICARES Medicus, Inc.
117.50
-2.08%
4771.TW Vizionfocus Inc.
161.00
-0.62%
1565.TWO St.Shine Optical Co.,Ltd.
188.00
-1.57%
4116.TWO BenQ Medical Technology Corporation
45.40
-0.11%